Jens Huober
0000-0002-8618-1820
Publication & Citation Trends
Publications
0 total
Abstract RF4-02: Efficacy Analysis of the Randomized Phase III DETECT V trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer
Cited by 0
Semantic Scholar
Abstract RF2-06: Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Substudy of the NSABP B-59/GBG-96-GeparDouze Trial
Cited by 0
Semantic Scholar
Abstract RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial
Cited by 0
Semantic Scholar
Abstract RF2-02: Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer
Cited by 0
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025 OA
Cited by 4
Semantic Scholar
292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial
Cited by 4
Semantic Scholar
P009: Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes OA
Cited by 0
Semantic Scholar
Overall Survival with Abemaciclib in Early Breast Cancer.
Cited by 20
Semantic Scholar
Research Topics
Breast Cancer Treatment Studies
(372)
HER2/EGFR in Cancer Research
(311)
Advanced Breast Cancer Therapies
(241)
Cancer Treatment and Pharmacology
(193)
Cancer Genomics and Diagnostics
(137)
Affiliations
University of Vermont
Goethe University Frankfurt
Novartis (Switzerland)
BC Cancer Agency
University of Udine